Latest news articles

Added 1 month ago Drug news

Phase III DECLARE-TIMI 58 results for Farxiga show reduced risk of hospitalisation from CV events.- AstraZeneca.

AstraZeneca announced positive full results from the DECLARE-TIMI 58 cardiovascular (CV) outcomes trial (CVOT) for Farxiga (dapagliflozin) which showed that...

Added 1 month ago Drug news

Phase III ODYSSEY OUTCOMES trial of Praluent shows fewer deaths from CV events-. Sanofi + Regeneron.

New analyses on mortality from the 18,924-patient phase III ODYSSEY OUTCOMES trial of Praluent (alirocumab), from Regeneron, shows it is...

Added 1 month ago Drug news

NEJM publishes positive results from Praluent cardiovascular outcomes trial.- Sanofi + Regeneron

The New England Journal of Medicine (NEJM) published positive detailed results of the 18,924-patient ODYSSEY OUTCOMES trial.The trial met its...

Search all news articles for Coronary atherosclerosis
 

Learning Zones

An epgonline.org Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.

Cardiovascular Metabolism Knowledge Centre

Cardiovascular Metabolism Knowledge Centre

The Cardiovascular Metabolism Knowledge Centre is an information hub providing expert insight into the management of hypertension and type 2 diabetes. This Knowledge Centre contains a wealth of scientific video content offering insights and opinion from some of the leading experts in the field.

Acute and Advanced Heart Failure

Acute and Advanced Heart Failure

What are the most effective treatments for acute heart failure? Can you define advanced heart failure? Discover here...

+ 3 more

Load more

Guidelines

Chest pain of recent onset: assessment and diagnosis

This guideline covers assessing and diagnosing recent chest pain in people aged 18 and over and managing symptoms while a diagnosis is being made.

Added 8 years ago

Cardiovascular disease: risk assessment and reduction, including lipid modification

This guideline covers the assessment and care of adults who are at risk of or who have cardiovascular disease (CVD), such as heart disease and stroke. It aims to help healthcare professionals identify people who are at risk of...

Added 4 years ago

2016 European Guidelines on cardiovascular disease prevention in clinical practice

The present guidelines represent an evidence-based consensus of the 6th European Joint Task Force  involving 10 professional societies.This document has...

Added 2 years ago

Search all guidelines for Coronary atherosclerosis
 

Journal articles

Association Between Baseline LDL-C Level and Total and Cardiovascular Mortality After LDL-C Lowering: A Systematic Review and Meta-analysis.

Objective: To evaluate whether baseline LDL-C level is associated with total and cardiovascular mortality risk reductions.

Added 3 months ago

Efficacy and Safety of Further Lowering of Low-Density Lipoprotein Cholesterol in Patients Starting With Very Low Levels: A Meta-analysis.

Objective: To evaluate efficacy and safety of further lowering LDL-C levels in patient populations presenting with median LDL-C levels of 1.8 mmol/L (70 mg/dL) or less.

Added 3 months ago

Safety and efficacy of the reducer: A multi-center clinical registry - REDUCE study.

The coronary sinus (CS) Reducer is a novel device designed to aid in the management and to improve quality of life of patients with severe angina symptoms refractory to optimal medical and interventional therapies.

Added 3 months ago

Search all journal articles for Coronary atherosclerosis
 

Clinical trials

Rivaroxaban for the Prevention of Major Cardiovascular Events in Coronary or Peripheral Artery Disease (COMPASS)

The primary purpose of this study is to evaluate whether treatment with rivaroxaban and aspirin or rivaroxaban alone is better than aspirin alone in prevention of heart attacks, stroke or cardiovascular death...

Added 6 years ago

An Efficacy and Safety Study for Rivaroxaban in Patients With Acute Coronary Syndrome

The purpose of this study is to determine whether rivaroxaban in addition to standard care reduces the risk of the composite of cardiovascular death, myocardial infarction, or stroke in patients...

Added 1 year ago

Testosterone Replacement in Older Men and Atherosclerosis Progression

As men grow older, their testosterone levels decrease with age.

Added 1 year ago

Search all clinical trials for Coronary atherosclerosis
 
My Urology Doc

I am a general urologist and men's health expert in Indianapolis, Indiana, U.S.A. I'm also an avid blogger and heath innovator. My social media brand, My Urology Doc, aims to make the formerly taboo world of urology more fun and appealing.

Men's Health: A Forgotten Topic

Men's health is a forgotten topic. To be honest, we men are mostly to blame. We've clung to our masculine misconceptions and repeatedly refused to engage the healthcare community. Who can blame us, we're invincible and we're going to live forever, right? Well, not exactly. Let's look at some of the reasons men's health is one of the least engaged topics in healthcare. 

CME

Anticoagulation

Accrediting body
BJC Learning
Credits available
5
Registration required
1
Subscription fee
0

Stable angina

Accrediting body
MIMS Learning - Monthly Index of Medical Specialities
Credits available
0
Registration required
1
Subscription fee
5

Cardiac rehabilitation

Accrediting body
Union of European Medical Specialists (via European Accreditation Council for CME)
Credits available
1
Registration required
1
Subscription fee
90
Search all CME for Coronary atherosclerosis